Health Economics›Waldenstroem macroglobulinemia›First-line therapy randomized data

First-line therapy randomized data

Waldenstroem macroglobulinemia · 10 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 4 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Ibrutinib and Rituximab Variant #02	—	R 209 656	28d	—	—	7	R 794 072 PFS proxy	1
Ibrutinib monotherapy Variant #01	—	R 81 964	28d	~44.1 mo	—	~2	~R 163 929 PFS proxy · indirect	15
Zanubrutinib monotherapy Variant #01	—	R 65 750	28d	—	—	~2	~R 131 500 PFS proxy · indirect	4
Bendamustine and Rituximab (BR) Variant #01	—	R 33 874	28d	~39.6 mo	—	~8	~R 270 994 PFS proxy · indirect	18
R-CHOP Variant #08	—	R 26 946	21d	~44.4 mo	—	~3	~R 80 838 PFS proxy · indirect	4
DRC Variant #01	—	R 26 242	21d	—	—	~6	~R 157 453 indirect	—
DRC (SC rituximab) Variant #01 Partial	—	R 26 242	28d	—	—	~6	~R 27 929 indirect	—
Fludarabine monotherapy Variant #05	—	R 13 754	28d	~16.5 mo	~52.9 mo	~6	~R 82 524 PFS proxy · indirect	4
Chlorambucil monotherapy Variant #03	—	R 2 355	28d	—	69.8 mo	13	R 30 610 PFS proxy	—
Rituximab monotherapy Variant #09 Partial	—	—	28d	20.3 mo	—	1	—	1

10 of 10 regimens shown